查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1632667

全球分叉病變市場：市場規模、佔有率、趨勢分析（按應用和地區）、細分市場預測（2025-2030 年）

Bifurcation Lesions Market Size, Share & Trends Analysis Report, By Application (Coronary, Peripheral), By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

分叉市場的成長和趨勢：

根據 Grand View Research, Inc. 的一份新報告，全球分叉病變市場規模預計到 2030 年將達到 35 億美元，2025 年至 2030 年的複合年成長率為 6.0%。

在預測期內，政府對技術開發和報銷的支持舉措可能會推動市場發展。

老齡人口的增加和不健康的生活方式是導致心血管疾病發生率不斷上升的原因。此外，未來幾年創新設備的核准和商業化程度不斷提高，以及預計用於治療分叉病變的新設備的進入，可能會推動市場的發展。

此外，負擔能力上升、微創手術需求增加、醫療旅遊崛起等因素也推動了全球整體對分叉病變手術的需求。根據多項研究，分叉病變手術約佔所有經皮冠狀動脈介入治療的20%。

分叉病變市場：概述

  • 分叉病變設備日益商業化以及產業參與者對研發的投資正在推動市場的發展，預計 2025 年至 2030 年期間複合年成長率約為 6.0%。
  • 由於心臟內血管網路複雜、設備可用性不斷提高以及對分叉病變手術干預的認知不斷提高，冠狀血管部分在 2024 年佔據了最大的市場佔有率。
  • 由於產業參與者對周邊應用設備開發的投資不斷增加，以及診斷技術的進步使得斑塊的準確檢測成為可能，周邊血管領域在未來幾年可能會呈現豐厚的成長。
  • 按地區分類，北美將在 2024 年佔據分叉病變市場的最大佔有率。由於藥物釋放型支架的需求不斷增加、分叉病變設備的商業化以及主要企業在該地區的擴張，預計未來它將保持主導地位。
  • 由於醫療保健基礎設施的改善、媒體驅動的旅遊業以及參與企業不斷增加的投資，亞太地區預計將成為未來十年成長最快的地區。
  • 市場的主要企業包括雅培、波士頓科學、康德樂、美Medtronic力、強生服務公司、CR Bard、Spectranetics 和Terumo Medical Corp.。開發了 Tryton 側支支架，該支架具有球囊擴張單絲支架輸送系統，可放置在側支動脈中治療分叉病變。該支架已在美國、歐洲、中東和非洲銷售。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

第 3 章 分叉病變市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 分岔市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL 分析

第 4 章 分叉病變市場：按應用的估計和趨勢分析

  • 分岔市場：應用儀表板
  • 分叉病變市場：應用趨勢分析
  • 分叉病變市場：按應用分類的市場規模預測和趨勢分析（2018-2030 年）
  • 冠狀動脈
  • 周圍血管

第5章 分叉病變市場：區域估計和趨勢分析（按應用和地區）

  • 全球分叉病變市場：區域儀表板
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第6章 競爭格局

  • 最新趨勢和影響分析：按主要製造商
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 主要企業市場佔有率分析（2023年）
    • Boston Scientific Corp.
    • Abbott
    • Cardinal Health
    • Medtronic
    • CR Bard, Inc.
    • Johnson &Johnson Services, Inc.
    • Spectranetics
    • Terumo Medical Corp.
    • Tryton Medical Inc.
Product Code: GVR-1-68038-534-2

Bifurcation Lesions Market Growth & Trends:

The global bifurcation lesions market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological developments and supportive government initiatives for reimbursement are likely to drive the market during the forecast period.

The increasing geriatric population and unhealthy lifestyle are responsible for growth in the incidence of cardiovascular disorders. Furthermore, an increase in approval & commercialization of innovative devices and the expected entry of new devices for the treatment of bifurcation lesions in the coming years are likely to drive the market.

In addition, factors such as rising affordability, increase in demand for minimally invasive procedures, and growing medical tourism are also boosting demand for bifurcation lesions procedures across the globe. According to various studies, procedures for coronary bifurcation lesions comprise approximately 20% of total percutaneous coronary interventions.

Bifurcation Lesions Market Report Highlights:

  • Increase in the commercialization of devices for bifurcation lesions and investments by industry players for R&D are the factors expected to boost the market, resulting in an anticipated CAGR of around 6.0% from 2025 to 2030
  • The coronary vascular segment accounted for the maximum share of the market in 2024 due to the presence of complex vascular network in heart, increased availability of devices, and rise in awareness regarding surgical interventions for bifurcation lesions.
  • The peripheral vascular segment is likely to witness lucrative growth in the coming years due to an increase in investments by industry players for the development of devices for peripheral application and advancements in diagnostics facilitating accurate detection of plaque.
  • Geographically, North America held the largest share of the bifurcation lesions market in 2024. It is anticipated to maintain its dominance in the coming years due to increasing demand for drug-eluting stents, commercialization of devices for bifurcation lesions, and the local presence of major market players.
  • The Asia Pacific is expected to observe the fastest growth over the next decade owing to improvement in healthcare infrastructure, medical tourism, and a rise in investments by market players in the region.
  • Some of the key players in the market are Abbott; Boston Scientific Corporation; Cardinal Health; Medtronic; Johnson & Johnson Services, Inc.; C. R. Bard, Inc.; Spectranetics; and Terumo Medical Corporation. Tryton Medical, Inc. developed the Tryton Side Branch Stent with a balloon-expandable, single-wire stent delivery system that can be deployed in the side branch artery for treatment of bifurcation lesions. The device is available in the U.S. and Europe as well as Middle East & Africa.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Regional scope
    • 1.2.3. Estimates and forecast timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity price analysis (Model 1)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application Segment
    • 2.2.2. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Bifurcation Lesions Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of congenital heart disease
      • 3.2.1.2. Increasing number of CVD incidence
      • 3.2.1.3. Increasing awareness among the population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Limited awareness and adoption
  • 3.3. Bifurcation Lesions Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Bifurcation Lesions Market: Application Estimates & Trend Analysis

  • 4.1. Bifurcation Lesions Market: Application Dashboard
  • 4.2. Bifurcation Lesions Market: Application Movement Analysis
  • 4.3. Bifurcation Lesions Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 4.4. Coronary
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Peripheral
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Bifurcation Lesions Market: Regional Estimates & Trend Analysis by Application, and Region

  • 5.1. Global Bifurcation Lesions Market: Regional Dashboard
  • 5.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 5.3. North America
    • 5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Key country dynamics
      • 5.3.2.2. Regulatory framework/ reimbursement structure
      • 5.3.2.3. Competitive scenario
      • 5.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Key country dynamics
      • 5.3.3.2. Regulatory framework/ reimbursement structure
      • 5.3.3.3. Competitive scenario
      • 5.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.3.4. Mexico
      • 5.3.4.1. Key country dynamics
      • 5.3.4.2. Regulatory framework/ reimbursement structure
      • 5.3.4.3. Competitive scenario
      • 5.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4. Europe
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.4.2. UK
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework/ reimbursement structure
      • 5.4.2.3. Competitive scenario
      • 5.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.3. Germany
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework/ reimbursement structure
      • 5.4.3.3. Competitive scenario
      • 5.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.4. France
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework/ reimbursement structure
      • 5.4.4.3. Competitive scenario
      • 5.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.5. Italy
      • 5.4.5.1. Key country dynamics
      • 5.4.5.2. Regulatory framework/ reimbursement structure
      • 5.4.5.3. Competitive scenario
      • 5.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.6. Spain
      • 5.4.6.1. Key country dynamics
      • 5.4.6.2. Regulatory framework/ reimbursement structure
      • 5.4.6.3. Competitive scenario
      • 5.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.7. Sweden
      • 5.4.7.1. Key country dynamics
      • 5.4.7.2. Regulatory framework/ reimbursement structure
      • 5.4.7.3. Competitive scenario
      • 5.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.8. Norway
      • 5.4.8.1. Key country dynamics
      • 5.4.8.2. Regulatory framework/ reimbursement structure
      • 5.4.8.3. Competitive scenario
      • 5.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.4.9. Denmark
      • 5.4.9.1. Key country dynamics
      • 5.4.9.2. Regulatory framework/ reimbursement structure
      • 5.4.9.3. Competitive scenario
      • 5.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.5.2. China
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework/ reimbursement structure
      • 5.5.2.3. Competitive scenario
      • 5.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.3. Japan
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework/ reimbursement structure
      • 5.5.3.3. Competitive scenario
      • 5.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.4. India
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework/ reimbursement structure
      • 5.5.4.3. Competitive scenario
      • 5.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.5. Australia
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework/ reimbursement structure
      • 5.5.5.3. Competitive scenario
      • 5.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.6. Thailand
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework/ reimbursement structure
      • 5.5.6.3. Competitive scenario
      • 5.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.7. South Korea
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework/ reimbursement structure
      • 5.5.7.3. Competitive scenario
      • 5.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6. Latin America
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.6.2. Brazil
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework/ reimbursement structure
      • 5.6.2.3. Competitive scenario
      • 5.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework/ reimbursement structure
      • 5.6.3.3. Competitive scenario
      • 5.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7. MEA
    • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 5.7.2. Saudi Arabia
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework/ reimbursement structure
      • 5.7.2.3. Competitive scenario
      • 5.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.3. South Africa
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework/ reimbursement structure
      • 5.7.3.3. Competitive scenario
      • 5.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.4. UAE
      • 5.7.4.1. Key country dynamics
      • 5.7.4.2. Regulatory framework/ reimbursement structure
      • 5.7.4.3. Competitive scenario
      • 5.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.7.5. Kuwait
      • 5.7.5.1. Key country dynamics
      • 5.7.5.2. Regulatory framework/ reimbursement structure
      • 5.7.5.3. Competitive scenario
      • 5.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Manufacturers
  • 6.2. Company/Competition Categorization
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2023
    • 6.3.4. Boston Scientific Corp.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Abbott
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. Cardinal Health
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Medtronic
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. C. R. Bard, Inc.
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Johnson & Johnson Services, Inc.
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Spectranetics
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Terumo Medical Corp.
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. Tryton Medical Inc.
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 Global bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 4 Global bifurcation lesions market, by region, 2018 - 2030 (USD Million)
  • Table 5 North America bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 6 North America bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 8 Canada bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 9 Mexico bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 10 Europe bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 11 Europe bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 12 UK bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 13 Germany bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 14 France bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 15 Italy bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 16 Spain bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 17 Denmark bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 18 Sweden bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 19 Norway bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 20 Asia Pacific bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 21 Asia Pacific bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 22 Japan bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 23 China bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 24 India bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 25 Australia bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 26 Australia bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 27 Thailand bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 28 South Korea bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 29 Latin America bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 30 Latin America bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 31 Brazil bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 32 Argentina bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 33 MEA bifurcation lesions market, by country, 2018 - 2030 (USD Million)
  • Table 34 MEA bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 35 South Africa bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 36 Saudi Arabia bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 37 UAE bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 38 Kuwait bifurcation lesions market, by application, 2018 - 2030 (USD Million)
  • Table 39 Participant's overview
  • Table 40 Financial performance
  • Table 41 Key companies undergoing expansions
  • Table 42 Key companies undergoing acquisitions
  • Table 43 Key companies undergoing collaborations
  • Table 44 Key companies launching new product types
  • Table 45 Key companies undergoing partnerships
  • Table 46 Key companies undertaking other strategies

List of Figures

  • Fig. 1 Bifurcation lesions market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Bifurcation lesions market outlook, 2024 (USD Million)
  • Fig. 10 Market Trends & outlook
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Bifurcation lesions application market share analysis, 2024 - 2030 (USD Million)
  • Fig. 14 Bifurcation lesions application market: Segment dashboard
  • Fig. 15 Coronary market, 2018 - 2030 (USD Million)
  • Fig. 16 Peripheral market, 2018 - 2030 (USD Million)
  • Fig. 17 Regional marketplace: Key takeaways
  • Fig. 18 North America bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 20 Canada bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 21 Mexico bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 22 Europe bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 23 UK bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 24 Germany bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 25 France bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 26 Italy bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 27 Spain bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 28 Denmark bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 29 Sweden bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 30 Norway bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 31 Asia Pacific bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 32 Japan bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 33 China bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 34 India bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 35 Australia bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 36 South Africa bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 37 Thailand bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 38 Latin America bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 39 Brazil bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 40 Argentina bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 41 MEA bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 42 South Africa bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 43 Saudi Arabia bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 44 UAE bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 45 Kuwait bifurcation lesions market, 2018 - 2030 (USD Million)
  • Fig. 46 Strategy framework